DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+35.64%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$291M
AUM Growth
+$291M
(+9.6%)
Cap. Flow
-$34.7M
Cap. Flow
% of AUM
-11.9%
Top 10 Holdings %
Top 10 Hldgs %
53.99%
Holding
96
New
7
Increased
8
Reduced
27
Closed
15
Top Buys
| 1 |
ProQR Therapeutics
PRQR
|
$8.45M |
| 2 |
AFMD
Affimed
AFMD
|
$3.11M |
| 3 |
OTIC
Otonomy, Inc.
OTIC
|
$1.8M |
| 4 |
Neuronetics
STIM
|
$1.3M |
| 5 |
NextCure
NXTC
|
$1.13M |
Top Sells
| 1 |
ALDR
Alder Biopharmaceuticals, Inc.
ALDR
|
$12M |
| 2 |
Ascendis Pharma
ASND
|
$4.5M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$3.95M |
| 4 |
Ardelyx
ARDX
|
$2.86M |
| 5 |
argenx
ARGX
|
$2.55M |
Sector Composition
| 1 | Healthcare | 91.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Stereotaxis
STXS
$261M
| $72.4M | 24.84% | 13,680,554 | – | – |
|
|
2
ProQR Therapeutics
PRQR
$237M
| $11M | 3.79% | 1,114,000 +852,479 | +326% | +$8.45M |
|
3
AtriCure
ATRC
$1.84B
| $10.4M | 3.56% | 318,729 | – | – |
|
|
ARQL
4
DELISTED
Arqule Inc
ARQL
| $9.94M | 3.41% | 497,762 -32,500 | -6% | -$649K |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $9.87M | 3.39% | 123,218 | – | – |
|
6
Galapagos
GLPG
$2.07B
| $9.72M | 3.34% | 47,000 -5,509 | -10% | -$1.14M |
|
7
Fate Therapeutics
FATE
$120M
| $9.2M | 3.16% | 470,000 | – | – |
|
|
SAGE
8
DELISTED
Sage Therapeutics
SAGE
| $9.01M | 3.09% | 124,806 | – | – |
|
9
DexCom
DXCM
$29.5B
| $7.95M | 2.73% | 36,338 | – | – |
|
10
iShares Biotechnology ETF
IBB
$5.6B
| $7.82M | 2.68% | 64,900 | – | – |
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $6.56M | 2.25% | 61,008 -3,500 | -5% | -$376K |
|
|
AERI
12
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $6.47M | 2.22% | 267,839 -19,909 | -7% | -$481K |
|
|
ZGNX
13
DELISTED
Zogenix, Inc.
ZGNX
| $5.57M | 1.91% | 106,749 -36,015 | -25% | -$1.88M |
|
|
TVRD
14
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $5.29M | 1.82% | 328,533 -50,391 | -13% | -$812K |
|
15
Akebia Therapeutics
AKBA
$833M
| $4.87M | 1.67% | 770,538 -57,500 | -7% | -$363K |
|
|
LMNX
16
DELISTED
Luminex Corp
LMNX
| $4.73M | 1.62% | 204,091 | – | – |
|
|
ARNA
17
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $4.49M | 1.54% | 98,942 +5,000 | +5% | +$227K |
|
18
Cytokinetics
CYTK
$4.23B
| $4.44M | 1.53% | 418,727 | – | – |
|
|
BHVN
19
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $4.07M | 1.4% | 74,700 -20,300 | -21% | -$1.11M |
|
|
20
Ascendis Pharma
ASND
$11.8B
| $3.91M | 1.34% | 28,100 -32,380 | -54% | -$4.5M |
|
21
VYNE Therapeutics
VYNE
$8.16M
| $3.7M | 1.27% | 797,565 -59,371 | -7% | -$276K |
|
22
Xenon Pharmaceuticals
XENE
$2.98B
| $3.26M | 1.12% | 248,854 -81,813 | -25% | -$1.07M |
|
|
AFMD
23
DELISTED
Affimed
AFMD
| $3.11M | 1.07% | +1,133,559 | New | +$3.11M |
|
|
ACHN
24
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $2.65M | 0.91% | 438,884 | – | – |
|
|
DRNA
25
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $2.61M | 0.89% | 118,314 | – | – |
|